


## DDO-02005

<b>Cat. No.:</b>	HY-144801A
<b>CAS No.:</b>	1186049-44-4
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>27</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	424.36
<b>Target:</b>	Potassium Channel
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	DDO-02005 is a potent Kv1.5 potassium channel inhibitor with an IC <sub>50</sub> value of 0.72 μM. DDO-02005 has good anti-atrial fibrillation (AF) effect in CaCl <sub>2</sub> -ACh AF rats model and effective anti-arrhythmic activity caused by aconitine <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.72 μM (Kv1.5 potassium channel) <sup>[1]</sup>	
<b>In Vivo</b>	DDO-02005 (0.1, 1, 3, 9 mg/kg; IV, single dosage) effectively combat the arrhythmogenic toxicity of aconitine in rats <sup>[1]</sup> . Pharmacokinetic Parameters of DDO-02005 in Sprague-Dawley rats <sup>[1]</sup> .	
	IV (1 mg/kg)	PO (1.25 mg/kg)
t <sub>1/2</sub> (h)	3.23 ± 1.07	6.25 ± 2.40
C <sub>max</sub> (μg/L)	90.23 ± 28.83	1.27 ± 0.40
AUC <sub>0-t</sub> (μg/L·h)	178.42 ± 39.33	4.41 ± 0.69
CL (L/h/kg)	5.83 ± 1.44	36.51 ± 2.54
MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

## REFERENCES

[1]. Zhao L, et al. Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors. *J Enzyme Inhib Med Chem.* 2022;37(1):462-471.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA